# Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients

> **NCT05155527** · PHASE2 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ivermectin Tablets
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05155527
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2022-06
- **Final completion:** 2022-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155527, "Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05155527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*